Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (196)
  2. Journal Article (66)
  3. Review (14)
  4. Research Letter (9)
  5. Correspondence (4)
  6. Editorial (4)
  7. Guidelines (2)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (143)
  2. Department of Medicine (142)
  3. Center for Hematologic Malignancies (139)
  4. Myeloma (131)
  5. Graduate Medical Education (129)
  6. GME, Medicine (120)

More Groups

People
  1. Alexander Lesokhin (114)
  2. Kylee Maclachlan (109)
  3. Sham Mailankody (99)
  4. Urvi Shah (99)
  5. Carlyn Rose Tan (93)
  6. Malin Hultcrantz (91)

More People

Years
  1. 2025 (15)
  2. 2024 (75)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (86)
  2. Clinical Lymphoma, Myeloma and Leukemia (79)
  3. Journal of Clinical Oncology (30)
  4. Blood Cancer Journal (14)
  5. Blood Advances (13)
  6. Oncology Research and Treatment (7)

More Publications

Publishers
  1. American Society of Hematology (99)
  2. Elsevier Inc. (91)
  3. American Society of Clinical Oncology (30)
  4. Nature Publishing Group (20)
  5. Elsevier Science, Inc. (10)
  6. S. Karger AG (7)

More Publishers

Results (296)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: An International Myeloma Foundation immunotherapy database real-world analysis: IMMUNOTHERAPY
    Correspondence

    Mian, H.; Martin, T. G.; Pond, G. R.; Asoori, S.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Abdallah, N.; Chhabra, S.; Parrondo, R.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial
    Journal Article

    Usmani, S. Z.; Facon, T.; Hungria, V.; Bahlis, N. J.; Venner, C. P.; Braunstein, M.; Pour, L.; Martí, J. M.; Basu, S.; Cohen, Y. C.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes: MULTIPLE MYELOMA, GAMMOPATHIES
    Journal Article

    Facon, T.; Moreau, P.; Weisel, K.; Goldschmidt, H.; Usmani, S. Z.; Chari, A.; Plesner, T.; Orlowski, R. Z.; Bahlis, N.; Basu, S.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes
    Journal Article

    Perrot, A.; Facon, T.; Plesner, T.; Usmani, S. Z.; Kumar, S.; Bahlis, N. J.; Hulin, C.; Orlowski, R. Z.; Nahi, H.; Mollee, P.; more...
    European Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group Study
    Journal Article

    Tan, C. R.; Asoori, S.; Huang, C. Y.; Brunaldi, L.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Bansal, R.; Silva Corraes, A. D. M.; Chhabra, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Outcomes of older adults and frail patients receiving idecabtagene vicleucel: A CIBMTR study
    Research Letter

    Akhtar, O. S.; Oloyede, T.; Brazauskas, R.; Afrough, A.; Hashmi, H.; Sidana, S.; Ahmed, N.; Bye, M.; Hansen, D.; Ferreri, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: Analysis of key subgroups of the MAIA study
    Journal Article

    Moreau, P.; Facon, T.; Usmani, S. Z.; Bahlis, N.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
    Journal Article

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Avutu, V.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
    Journal Article

    Perica, K.; Jain, N.; Scordo, M.; Patel, R.; Eren, O. C.; Patel, U.; Gundem, G.; Domenico, D.; Mitra, S.; Socci, N. D.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save